- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of June 3
The Center for Biosimilars® recaps the top stories for the week of June 3, 2019.
Transcript
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of June 3.
Number 5: Prestige BioPharma announced that the European Medicines Agency will review its application for a proposed trastuzumab biosimilar, HD201.
Number 4: During this week’s 2019 American Society of Clinical Oncology Annual Meeting (ASCO), researchers presented the final overall survival results from the phase 3 HERITAGE study of biosimilar trastuzumab, Ogivri.
Number 3: Also at ASCO, Samsung Bioepis presented long-awaited 3-year results for its biosimilar trastuzumab, Ontruzant.
Number 2: With patents on reference products that treat multiple sclerosis set to expire soon in Latin America, a panel of experts published a set of recommendations on biosimilars in the region.
Number 1: Ahead of the anticipated 2019 marketing of FDA-approved anticancer biosimilars in the United States, a pharmacy benefit manager is launching an oncology biosimilar program.
Finally, last week, our e-newsletter asked whether you think other states will follow Colorado’s lead in capping patients’ costs for insulin.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
